Background. Histoplasmosis is an endemic fungal disease with diverse clinical presentations. Histoplasmosis-associated hemophagocytic lymphohistiocytosis (HLH) is a rare disorder with limited data regarding treatment and outcome. We described the clinical features, treatment, and outcomes of five patients in our institution with histoplasmosis-associated HLH.
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare but often life-threatening syndrome of excessive immune activation. Primary HLH is triggered by genetic disorders and usually manifests in children below the age of 18 months. e term secondary (acquired) HLH has generally been used to describe cases in adults without known genetic predisposition and a clear trigger for HLH. is trigger is often an infection or an alteration in immune homeostasis (e.g., malignancy, rheumatologic conditions, or immunodeficiency syndromes) [1] . HLH may present as a single episode of disease or recurrent episodes. Histoplasmosis-associated HLH is a relatively rare disorder with limited data about treatment [2, 3] . We describe the clinical features, treatment, and outcomes of cases seen at the University of Kansas Medical Center (KUMC). In addition, we reviewed the current literature about diagnosis and treatment of histoplasmosis-associated HLH.
Methods
We searched our medical informatics HERON (Healthcare Enterprise Repository for Ontological Narration) database for the following ICD9/ICD10 terms: "hemophagocytic syndrome," "hemophagocytosis," "hemophagocytic lymphohistiocytosis" or "macrophage activation syndrome" and "histoplasmosis" or "disseminated histoplasmosis." We included patients older than 18 years and seen at our institution from 1/1/2006 to 9/30/2017. All patients who satisfied the HLH-04 criteria [4] for a diagnosis of HLH (i.e., 5 of 8 criteria) and confirmed to have histoplasmosis by retrospective chart review were included. HLH-04 criteria include (1) fever; (2) splenomegaly; (3) cytopenia in two or more cell lines; (4) hypertriglyceridemia (triglyceride level ≥265 mg/dL or hypofibrinogenemia (fibrinogen level ≤150 mg/ dL); [5] hemophagocytosis in the bone marrow, spleen, or lymph nodes; [6] hyperferritinemia (ferritin level ≥500 ng/mL); [7] impaired NK cell function; and [8] elevated soluble CD25 (soluble IL-2 receptor alpha) two standard deviations above ageadjusted laboratory-specific norms. is study was approved by the University of Kansas Medical Center institutional board review.
Literature Review
We searched PubMed for "histoplasmosis" and "hemophagocytic syndrome," "histoplasmosis" and "secondary hemophagocytic syndrome," "histoplasmosis induced hemophagocytic syndrome," "disseminated histoplasmosis" and "hemophagocytic syndrome," "HLH" and "histoplasmosis," and "histoplasma associated HLH." Few papers were only available by a Google search. We included all case reports/series with a published abstract in English.
Results
We identified five cases of histoplasmosis-associated HLH.
e clinical characteristics are summarized in Table 1 . All patients had disseminated histoplasmosis and were immunosuppressed. Human immunodeficiency virus (HIV) infection was the underlying condition in 2/5 patients (40%); the diagnosis of HIV in both patients was new. e other three patients were on steroids in addition to other immunosuppressive agents. ere was a male predominance 4/5 (80%). All patients 5/5 (100%) had positive blood cultures for histoplasma, and the histoplasma antigen (blood or urine) was above the limit of quantification. Histoplasma was seen on bone marrow (BM) biopsy in 3/4 (75%) patients.
Four patients (80%) met at least 5 out of 8 criteria for the diagnosis of HLH as shown in Table 2 . e IL2-receptor, cytopenia, and ferritin criteria were met in all five patients. Peak ferritin level was above the limit of quantification in 4/5 (80%) patients. One patient met only four criteria, but the hematology consulting team felt that it was highly likely secondary HLH. e treatment and outcomes are shown in Table 3 . Most patients were started on liposomal amphotericin B for at least 2 weeks and then transitioned to an oral azole. One patient received only voriconazole. ree out of five patients survived to hospital discharge. e literature review yielded 60 cases from 39 papers; most of them were case reports and few were case series. Table 4 summarizes the patients baseline characteristics, treatment used, diagnostic tests for histoplasmosis, and outcomes. Five papers were published before 2000, and 18 papers were published since 2015. We report five patients at our institution from 1/1/2006 to 9/30/2017 ( Table 1 ). All 5 cases at KUMC were diagnosed after 2010. Adding our five cases to the 60 reported previously, the median age of cases was 41 years and 72% (37/52) were men. e most common underlying immunosuppressive condition was HIV in 62% (36/58). Six patients had solid organ transplant, and there was no clear underlying immunodeficiency described in seven patients. In eleven patients, there was no mention of the host immune status. e median CD4 count in HIV patients was 17 cells/μL. e majority of patients had disseminated histoplasmosis. Five patients were diagnosed by either lymph node biopsy or histoplasma urine Ag only and not proven to have disseminated histoplasmosis.
Initial antifungal treatment consisted of amphotericin B formulation in 48 cases and only azoles in four cases. e specific treatment for HLH was as follows: nine patients received steroids only, six patients received intravenous immunoglobulin (IVIG) only, three patients received dexamethasone and etoposide, two patients received etoposide, dexamethasone, and cyclosporine, two patients received steroids and IVIG, and one patient received Anakinra and IVIG. e overall inpatient case fatality rate was 31% (20/64) and 37% (13/35) among HIV patients. e mortality rate 
Discussion
Histoplasmosis-associated HLH is rare but likely underdiagnosed given the nonspecific clinical and laboratory presentation. e diagnosis is challenging because high fever, peripheral blood cytopenia, splenomegaly, and elevated ferritin are very common in patients with disseminated histoplasmosis. We report the second largest case series of histoplasmosis-induced HLH. About half of the cases (29/60) were reported after 2014, and all five cases at our institution were diagnosed after 2010. is may be explained by an increased awareness of this entity. Almost all cases of histoplasmosis-associated HLH occurred in patients with disseminated histoplasmosis. Most patients were relatively young. HIV and its numerous related opportunistic infections remain the most common underlying immunodeficiency that triggers HLH, but the recent literature showed an increasing number of non-HIV patients (organ transplant, patients receiving chemotherapy, or other immunosuppressive treatments). is is likely caused by the recent increase in disseminated histoplasmosis among non-HIV infected patients [43, 44] . Only few patients had no clear underlying immunodeficiency. e male predominance may be related in part to the higher incidence and prevalence of HIV in men in the United States.
Human immunodeficiency virus (HIV) could trigger hemophagocytic syndrome by itself, or secondary to ART initiation or opportunistic infections [45] . In a retrospective study to evaluate the triggers of HLH among HIV patients in Brazil, opportunistic infections were the most common factors (59%) including Mycobacterium (34%), Cytomegalovirus (14%), and Cryptococcus neoformans (11%) [46] .
Macrophage activation syndrome (MAS) is a form of HLH that is usually associated with rheumatologic diseases and inflammatory bowel diseases (IBD). In a review of literature of 50 cases of HLH or MAS, the association between HLH and IBD was thought to be secondary to infections, the effect of immunosuppressive therapy, and the potential presence of a genetic susceptibility [47] . e majority of cases were Crohn's disease (CD) rather than ulcerative colitis; this was attributed to the more frequent use of immunomodulators in CD. e number of patients in each treatment group and the noncontrolled nature of this review hinder making conclusions about the most effective therapy. Patients who received amphotericin B had a slightly lower case fatality rate compared to the whole group. It is unclear if the addition of etoposide and steroids was helpful, but 4/5 patients with such regimen survived. We suggest starting a lipid formulation of amphotericin B as soon as possible, as recommended by the Infectious Diseases Society of America guidelines [48] for the treatment of moderate to severe disseminated histoplasmosis. ere are limited data to establish the best treatment protocol and the role of immunosuppressive therapy and IVIG for histoplasma-associated HLH [1] . e treatment of secondary HLH is most effective when the inciting disease can be treated and controlled. If effective histoplasmosis treatment fails to demonstrate improvement after 48-72 hours, clinicians often consider initiation of Canadian Journal of Infectious Diseases and Medical Microbiology [49] . Once clinical improvement is noted, we believe immunosuppressive therapy can be tapered, and the full protocol is often not required. We report a small number of cases at our institution and it is possible that we could have missed cases in our retrospective search. In published case reports and case series, some data were lacking and few articles were not in English.
Conclusions
Histoplasmosis-associated HLH among adults is an uncommon but serious disease with high mortality. e clinical and laboratory findings that should prompt evaluation for HLH are splenomegaly, highly elevated ferritin, and cytopenia in an immunocompromised patient with disseminated histoplasmosis. e delay in diagnosis of HLH may affect outcomes and patients with suspected HLH should have a prompt hematology consultation. HLH appears to be a disease of excessive immune activation, and the optimal treatment and duration of immunosuppressive therapy remains unknown. Early antifungal therapy with a lipid formulation amphotericin B is critical. Multicenter prospective studies are needed to help define the role and duration of immunosuppressive therapy for this disease.
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